Large and small drugmakers are vying for a piece of what analysts view as one of the biggest market opportunities in the pharma industry's history. Here’s what’s coming next.

The startup is developing medicines designed to overstress cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.” ...

The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.

Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage." ...

Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ...

Newly disclosed Phase 3 results presented Friday match findings the biotech disclosed last year, while offering a more comprehensive look at how its drug stacks up to rival therapies.

The new policy aims to ensure important diagnostics remain available to patients, but some experts caution the increased regulatory burden could slow access to testing.

Increasing the production capacity for Zepbound and Mounjaro is “the most ambitious expansion plan in our company’s history,” said CEO David Ricks.

The funds will help the cancer-focused startup Enlaza bring several candidates toward human testing in the next few years, its CEO said.

First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.